Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. A. Rachel Leheny Ph.D. | CEO & Director | 852.84k | -- | 1963 |
| Mr. Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board | 757.4k | -- | 1964 |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer | 615.59k | -- | 1953 |
| Mr. Michael J. Dunn M.B.A., MBA | President & COO | -- | -- | 1956 |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor | -- | -- | -- |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor | -- | -- | -- |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor | -- | -- | -- |
| Mr. John M. Dunn J.D. | General Counsel | -- | -- | 1952 |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer | -- | -- | 1965 |
| Ms. Raven D. Jaeger M.S. | Chief Regulatory Officer | -- | -- | -- |
CalciMedica, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Corporate Governance
Upcoming Events
March 26, 2025 at 12:30 PM UTC - March 31, 2025 at 12:30 PM UTC
CalciMedica, Inc. Earnings Date